CTOs on the Move

ViaCyte

www.viacyte.com

 
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.viacyte.com
  • 3550 General Atomics Court
    San Diego, CA USA 92121
  • Phone: 858.207.0500

Executives

Name Title Contact Details
Steven White
Chief Technology Officer Profile

Funding

ViaCyte raised $10M on 09/25/2018
ViaCyte raised $80M on 11/29/2018
ViaCyte raised $53.9M on 04/22/2021

Similar Companies

Ann Arbor Bio Research / MicroDose Life Sciences

Arbor Biotechnologies is an early stage life sciences company pushing the boundaries of biodiscovery. Using artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, we are accelerating the discovery of proteins...

Ordaos Bio

Ordaos is a human-enabled, machine-driven drug design company.

Biocentric Solutions

Biocentric Solutions, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Highline Sciences

Highline Sciences is a specialized, full-service CRO and consultancy founded from within an oncology biotech to provide a better solution. We understand the gap between what you need and what you get from a traditional CRO and we’re here to improve the...

Exosome Diagnostics

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company`s proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.